Tenon Medical entered into a warrant inducement agreement on September 11, 2026, with an institutional investor to exercise outstanding Series A warrants for 572,179 shares at $5.02 per share, generating approximately $2.87 million in gross proceeds. In exchange, the company issued new unregistered five-year Series B warrants to purchase up to 858,269 shares (150% of the underlying shares) at an exercise price of $5.02 per share. The transaction closed on September 14, 2026, with proceeds designated for working capital and general corporate purposes. WallachBeth Capital LLC served as financial advisor, receiving a 7% fee plus up to $65,000 in reimbursable expenses. Tenon Medical is a medical device company specializing in minimally invasive surgical systems for sacroiliac joint fusion.
